Browse the evidence

Semaglutide treatment reduces plasma levels of FABP4 and modulates neutrophil phenotype (increasing CD88, reducing CD11b-mediated adhesion), thereby attenuating prothrombotic and atherosclerotic mechanisms.

For patients with Type 2 Diabetes and obesity who are not controlled on oral medications, Semaglutide (0.5-1.0 mg weekly) not only aids weight loss but may also reduce specific cardiovascular risk markers like FABP4 and improve neutrophil behavior, potentially lowering atherosclerosis risk. This benefit is observed after 6 months of treatment.

In human visceral and subcutaneous adipose tissue, p38α (Mapk14) mRNA levels inversely correlate with Body Mass Index (BMI) and positively correlate with UCP1 expression.

Humans with higher BMI tend to have lower levels of p38α mRNA in their fat tissue, and this lower level is linked to lower levels of the fat-burning protein UCP1. This suggests that restoring p38α might not be the direct solution, as its role is complex (inhibitory in BAT), but it highlights a biomarker of reduced fat-burning capacity in obesity.

Berberine (BBR) shows multi-target anti-obesity actions in preclinical models (AMPK activation, gut microbiota modulation) but suffers from poor oral bioavailability (<5%) and lacks sufficient clinical validation for obesity.

Berberine is a natural compound with preclinical evidence for weight loss, but it has very low absorption in the body (<5%) and hasn't been proven effective in large clinical trials for obesity. While safe for other uses, it is not yet a recommended treatment for weight loss.

GLP-1 receptor agonists (specifically liraglutide and exendin-4) inhibit cancer progression and proliferation in various malignancies (breast, prostate, pancreatic, ovarian, colon, liver) through mechanisms including apoptosis induction, cell cycle arrest, and inhibition of signaling pathways like PI3K/Akt/mTOR and MAPK.

This paper highlights that while semaglutide (Ozempic/Wegovy) has mixed signals regarding cancer risk in humans, other GLP-1 agonists like liraglutide and exendin-4 have demonstrated anti-cancer effects in laboratory and animal studies. For patients, this underscores the importance of discussing specific drug risks with a doctor, especially those with a history of cancer, as the effect is not uniform across all drugs in this class.

The appetite-suppressing effects of GLP-1 analogs attenuate during the weight maintenance phase, suggesting that the biological drive to lose weight diminishes once a new homeostatic fat mass is reached.

As you reach your target weight, the strong appetite suppression from GLP-1 medications may lessen. This is a normal physiological response as your body adjusts to its new weight. Continued monitoring and potentially lifestyle adjustments may be needed to maintain weight loss.

For Semaglutide, higher doses are associated with a higher risk of intolerable gastrointestinal adverse reactions.

If you are taking Semaglutide and experiencing intolerable gastrointestinal side effects, discuss with your doctor whether a lower dose (e.g., 0.5mg) might be sufficient to manage your condition with fewer side effects, as higher doses (1mg) are associated with a higher risk of these reactions.

The protective association between plant-based diets and weight loss is weaker or absent in individuals with existing obesity compared to those with normal or overweight status.

If you have obesity, you may find weight loss more challenging with plant-based diets due to metabolic factors like insulin resistance. However, focusing on healthful plant foods remains important for overall health and may still support weight management, even if the effect is less pronounced than in non-obese individuals.

GLP-1 receptor agonists are associated with a rapid worsening of diabetic retinopathy, particularly in patients with a history of retinopathy and those using insulin, likely due to rapid glycemic improvement.

If you have diabetes and are starting a GLP-1 medication, ensure you have regular eye exams. If you already have eye problems, your doctor may monitor you more closely, as rapid blood sugar improvement can temporarily worsen vision.

Intermittent fasting (IF) is a suboptimal dietary strategy for optimizing muscle protein remodeling and maintaining muscle mass because prolonged fasting periods increase muscle protein breakdown (MPB) and reduce the frequency of muscle protein synthesis (MPS) stimulation, leading to a less favorable net protein balance compared to balanced meal feeding.

If your goal is maximizing muscle size or quality, avoid long fasting windows (e.g., >16 hours) if possible. Spread your protein intake across 3-4 meals every 3-5 hours to keep muscle protein synthesis stimulated. If you practice IF for fat loss, ensure you consume enough total protein (≥1.6 g/kg/day) and consider resistance training to mitigate potential muscle loss.

Genetic variants (SNPs) associated with obesity have modest individual effects, but aggregated into genetic risk scores, they can interact with environmental factors (diet, activity) to amplify obesity risk.

Your genes play a role in your weight, but they are not the whole story. Environmental factors like diet and activity can amplify genetic risk. Managing these factors is crucial for those with a genetic predisposition to obesity.

Pharmacogenomics can partially explain heterogeneous responses to weight loss medications by identifying genetic variants that affect drug metabolism or receptor binding.

Current weight loss medications work differently for different people, partly due to genetics. While pharmacogenomic testing is not yet standard, it holds promise for predicting who will benefit from specific drugs like topiramate or liraglutide.

Exogenous oxytocin administration reduces body weight and food intake in diet-induced obese rodents and non-human primates by acting on oxytocin receptors in the hindbrain (NTS) and hypothalamus to enhance satiety signals and increase energy expenditure.

Research suggests oxytocin may help reduce food intake and increase energy expenditure in obese individuals, particularly those with leptin resistance. However, current human trials are short-term, and long-term safety and optimal dosing (especially via intranasal spray) are still being determined. It is not yet a standard, widely available treatment for obesity.

Females have higher T2DM-related mortality rates than males globally, although males show a greater rate of increase in Disability-Adjusted Life Years (DALYs) over time.

Be aware that women face higher T2DM mortality rates than men globally. While men are seeing a faster rise in disease burden, women currently bear a heavier mortality toll. Both sexes should prioritize prevention, but women may need to be particularly vigilant about early diagnosis and management.

A higher polygenic score for BMI is associated with lower weight loss following bariatric surgery, although the effect size is modest and attenuates in sensitivity analyses.

If you are considering bariatric surgery, having a high genetic risk for obesity might mean you lose slightly less weight than someone with low genetic risk. However, the surgery is still very effective. You may need to be more vigilant with lifestyle changes or consider adjunct therapies like GLP-1 RAs to maintain your results.

Inhibitors of hepatic lipogenesis (including ACLY, ACC, FAS, SCD1, and DGAT2 inhibitors) reduce liver fat content in MASLD, but some (like ACC inhibitors) may increase serum triglycerides, necessitating combination therapies (e.g., ACC + DGAT2 inhibitors) to mitigate adverse lipid effects.

Several new drugs target the liver's fat-making enzymes (like ACC and FAS). While they reduce liver fat, some can raise blood triglycerides. To avoid this, doctors may combine an ACC inhibitor with a DGAT2 inhibitor. These are still largely in clinical trials and are not yet first-line treatments compared to GLP-1 agonists.

Higher visceral adiposity, quantified by the Lipid Accumulation Product (LAP), is strongly associated with an increased risk of declined renal function (eGFR < 60 mL/min/1.73m2) in the general population, independent of traditional risk factors like diabetes and hypertension.

To protect your kidney function, focus on reducing visceral fat, not just total body weight. Use the Lipid Accumulation Product (LAP) concept: combine your waist circumference with your Triglyceride levels. A high LAP score indicates higher visceral fat and a significantly higher risk of kidney dysfunction, even if your BMI is normal. Managing this requires lifestyle interventions like caloric restriction and physical activity to lower both waist size and triglycerides.

SGLT2 inhibitors reduce hepatic lipid content and liver enzymes in patients with MASLD and Type 2 Diabetes, but histological evidence for treating MASH is still required.

If you have diabetes and fatty liver, SGLT2 inhibitors (like dapagliflozin) are a good option to lower liver fat and enzymes. They work by changing how your body handles sugar and fat. However, they are not yet proven to reverse the scarring of MASH, so they are part of a broader management strategy.

Long-term high-level endurance training does not preserve or enhance the capacity for myofibrillar protein synthesis (iMyoPS) in response to unaccustomed resistance exercise in older adults compared to untrained age-matched peers.

If you are an older adult who has done endurance sports for decades, don't assume your muscles will automatically build or maintain mass when you start lifting weights. Your history of running or cycling does not protect you from 'anabolic resistance' to resistance exercise. You likely need to approach resistance training with the same diligence as an untrained peer, focusing on progressive overload and adequate protein intake, as your chronic training history offers no special advantage in muscle protein synthesis rates.

Weekly GLP-1 receptor agonists significantly reduce MACE risk in obese T2DM patients, whereas daily GLP-1 RAs do not show a significant reduction compared to placebo.

For obese diabetic patients, choosing a weekly GLP-1 injection (like dulaglutide or semaglutide) may offer better heart protection than daily options (like liraglutide or lixisenatide), according to this analysis. However, the difference between the two classes was not statistically significant when compared directly to each other.

The peptide triple agonist GEP44, targeting GLP-1, Y1, and Y2 receptors, promotes profound weight loss and glycemic control in diet-induced obese rats without triggering the nausea or malaise associated with standard GLP-1 receptor agonists.

This research highlights a promising new class of drugs (triple agonists like GEP44) that may offer superior weight loss and blood sugar control compared to current GLP-1 medications, without causing the nausea that often stops people from taking them. However, this is currently only proven in animals, not humans. For now, standard GLP-1s remain the primary option, but patients experiencing intolerable side effects might discuss clinical trials or future availability of these multi-agonists with their healthcare provider.

GLP-1RAs activate neurons in the paraventricular nucleus (PVH) and ventromedial hypothalamus (VMH) to suppress food intake and increase energy expenditure or thermogenesis.

GLP-1 medications also target other brain regions (PVH and VMH) to suppress food intake and increase energy expenditure. This helps explain why these medications can lead to weight loss even without significant changes in diet or exercise.

GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.

The addition of GIP receptor activation in dual agonists may help improve insulin sensitivity through metabolic pathways in fat tissue, independent of just losing weight.

Adjunctive liraglutide 1.8 mg for 6 months following laparoscopic adjustable gastric banding (LAGB) provides no significant additional improvement in HbA1c or body weight compared to LAGB alone, and cessation of therapy leads to significant weight regain and worsening glycemic control relative to placebo.

If you have had a gastric band and are considering adding Liraglutide (Victoza) for 6 months, current evidence suggests it will not provide extra weight loss or blood sugar benefits during that time, and you may regain more weight after stopping it compared to not taking it. This does not rule out other GLP-1 drugs (like Semaglutide) or longer durations, but for this specific protocol, it is not recommended.

Social media platforms (Instagram, TikTok) misrepresent semaglutide by promoting off-label weight loss use while omitting common adverse effects like gastrointestinal disorders, leading to unreflected medication use and supply shortages for indicated patients.

If you are considering semaglutide for weight loss, understand that it is a prescription medication with significant side effects, primarily gastrointestinal issues. Social media often omits these risks. Consult a healthcare provider to ensure it is appropriate for you and to avoid contributing to shortages for diabetic patients.